Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology & Oncology Physician in Chapel Hill, NC
NPI: 1154563260Primary Practice Location
UNC HOSPITALS
101 Manning Dr, Chapel Hill, NC
Primary Employer
UNC Faculty Physicians
uncmedicalcenter.org
HQ Phone
Get DO, MPH Christopher's Phone Numberphone_androidMobile
Get DO, MPH Christopher's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMA State Medical License
NC State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 94 | 208 |
| 2 | 99205New patient office or other outpatient visit, typically 60 minutes | 45 | 45 |
| 3 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 29 | 141 |
| 4 | 99214Established patient office or other outpatient visit, 30-39 minutes | 21 | 21 |
| 5 | 99239Hospital discharge day management, more than 30 minutes | 17 | 19 |
Authors: Rabia Saleem, Rana Mckay, Nerea Lopetegui-Lia, Amin Nassar, Brinda Emu, Melissa Lechner, Neil Shah, Elad Sharon, Arjun Mittra, Claire Drolen, Sonam Puri, Guru Sonpavde, Dame Idossa, Paul Rubinstein, Ankit Mangla, Caroline Nebhan, Veli Bakalov, Kathryn Lurain, Alexandra Drakaki, Elizabeth Chiao, Parminder Singh, Mingjia Li, Erin Reid, Aarthi Rajkumar, Tarek Mouhieddine, Thomas Marron, Toni Choueiri, Bailey Fitzgerald, Nazli Dizman, Adewunmi Falohun, Lindsey Baden, Robert Baiocchi, Vaia Florou, Vishal Shah, Pauline Funchain
Journal: J Clin Oncol
Publication Date: 2023-05-16
Authors: Natalie Grover, Astha Thakkar, Anne Beaven
Journal: Hematology Am Soc Hematol Educ Program
Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas.
Authors: Natalie Grover, Anne Beaven, Nicholas Tschernia
Journal: J Immunother Cancer
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Bone Marrow Biopsy, DRUG: Venetoclax, PROCEDURE: Positron Emission Tomography, PROCEDURE: Biospecimen Collection, DRUG: Cyclophosphamide, DRUG: Prednisone, DRUG: Etoposide, DRUG: Vincristine Sulfate, BIOLOGICAL: Rituximab, PROCEDURE: Computed Tomography, DRUG: Doxorubicin Hydrochloride, PROCEDURE: Lumbar Puncture
Lead Sponsor: UNC Lineberger Comprehensive Cancer Center
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Intervention / Treatment: DRUG: ATLCAR.CD30 cells
Lead Sponsor: Wake Forest University Health Sciences
Collaborators: Bristol-Myers Squibb, Atrium Health Levine Cancer Institute
Intervention / Treatment: DRUG: Nivolumab
